CB-5083: A Selective p97 Inhibitor for Advanced Tumor Research

Principle and Setup: Leveraging CB-5083 for Protein Homeostasis Disruption

CB-5083 is a next-generation, orally bioavailable, and highly potent inhibitor of the AAA-ATPase p97 (valosin-containing protein, VCP), a central regulator of protein homeostasis. By selectively targeting the second ATPase domain of p97 with an IC₅₀ of 15.4 nM, CB-5083 competitively blocks ATP binding, disrupting the extraction and degradation of poly-ubiquitinated proteins via the ubiquitin-proteasome system. This results in the accumulation of misfolded proteins, robust activation of the unfolded protein response (UPR), and subsequent induction of apoptosis, particularly in cancer cells where proteostasis is under heightened stress. Notably, CB-5083 has demonstrated significant tumor growth inhibition (TGI up to 63%) in diverse in vivo xenograft models, including colorectal adenocarcinoma, non-small-cell lung cancer, and multiple myeloma, highlighting its translational relevance in oncology research.

The AAA-ATPase p97 is also tightly linked to ER-associated degradation (ERAD), membrane biogenesis, and lipid homeostasis. Recent mechanistic studies, such as the Carrasquillo Rodríguez et al. (2024) investigation, reinforce the centrality of p97 in balancing ER expansion and lipid storage, with implications for both cancer and metabolic disease models. Thus, CB-5083 serves as a precision tool to interrogate these intertwined pathways.

Experimental Workflow: Stepwise Application of CB-5083 in Cellular and In Vivo Models

1. Compound Preparation and Handling

• Solubilization: CB-5083 is insoluble in water but dissolves readily in DMSO (>20.65 mg/mL) or ethanol (>4.4 mg/mL). For optimal solubilization, gently warm the vial to 37°C and, if necessary, apply brief ultrasonic treatment. Prepare fresh aliquots to avoid degradation; long-term storage of solutions is discouraged.
• Storage: Store CB-5083 as a solid at -20°C, desiccated and protected from light.

2. In Vitro Protocols

1. Cell Line Selection: CB-5083 has been validated in HEK293T, A549 (lung carcinoma), and HCT116 (colorectal cancer) cells. For apoptosis and UPR readouts, select cell lines with robust ER-associated degradation and p97 expression.
2. Treatment Regimens: Prepare working concentrations (e.g., 0.01–10 µM) by serial dilution in culture media, maintaining a final DMSO concentration <0.1% v/v.
3. Assay Readouts:
   • Monitor accumulation of poly-ubiquitinated proteins and TCRα-GFP by immunoblotting or fluorescence microscopy.
   • Assess UPR activation via markers such as CHOP, ATF4, and BiP by qRT-PCR or immunoblotting.
   • Quantify apoptosis using caspase-3/7 activity assays or Annexin V/PI staining.
4. Controls: Include vehicle (DMSO) controls and, where possible, p97 knockdown as a genetic comparator to confirm specificity.

3. In Vivo Studies

• Model Selection: Employ mouse xenograft models of colorectal adenocarcinoma, NSCLC, or multiple myeloma. Oral dosing of CB-5083 (per published regimens) has demonstrated TGI up to 63%.
• Pharmacodynamic Readouts: Evaluate tumor size, protein ubiquitination status in tumor tissue, and apoptosis markers post-treatment.
• Safety Considerations: Monitor for off-target toxicity and body weight changes, adjusting dosing as necessary.

Advanced Applications and Comparative Advantages

CB-5083 offers several unique advantages in dissecting the nexus between protein homeostasis disruption, ER stress, and cancer cell fate:

• Precision in Targeting p97: Unlike pan-proteasome inhibitors, CB-5083 selectively blocks the p97 AAA-ATPase, allowing researchers to parse ERAD-specific events and downstream UPR signaling without confounding global proteasome inhibition effects.
• Integration with ER Lipid Research: The reference study by Carrasquillo Rodríguez et al. (2024) demonstrates how ER-associated phosphatases (e.g., CTDNEP1) regulate both membrane expansion and lipid droplet formation, processes intimately linked to p97 function. CB-5083 enables perturbation of p97-dependent protein extraction, providing a platform to study how ER stress and lipid homeostasis intersect in health and disease.
• Quantifiable On-Target Activity: Dose-dependent accumulation of poly-ubiquitinated proteins and UPR markers, as well as measurable TGI in animal models, offer robust, reproducible endpoints for translational research.
• Clinical Relevance: As CB-5083 has advanced to phase 1 clinical trials for multiple myeloma and solid tumors, its application in preclinical studies provides a direct bridge to translational and therapeutic discovery pipelines.

For further perspective, the article "CB-5083: A Selective p97 Inhibitor Transforming Tumor Research" complements these findings by highlighting CB-5083's superiority over less selective p97 inhibitors in driving apoptosis and tumor regression, while "CB-5083: Selective p97 Inhibition as a Precision Tool for..." extends the narrative to ER lipid regulation and metabolic disease models, emphasizing broader systems biology applications.

Troubleshooting and Optimization Tips

Compound Handling

• Solubility Issues: If CB-5083 does not fully dissolve in DMSO or ethanol, gently warm to 37°C and apply brief ultrasonic pulses. Avoid repeated freeze-thaw cycles and prepare working solutions fresh for each experiment.
• Solution Stability: CB-5083 solutions are not stable for long-term storage; aliquot and store at -20°C as a solid to maximize shelf life.

Biological Assay Optimization

• Non-specific Toxicity: High concentrations (>10 µM) may induce off-target toxicity. Titrate doses carefully and monitor cell viability to distinguish specific p97 inhibition from general cytotoxicity.
• Assay Sensitivity: For UPR and apoptosis endpoints, optimize assay windows (typically 6–48h post-treatment) for maximal signal-to-noise. Use multiplexed readouts (e.g., immunoblotting plus flow cytometry) to corroborate findings.
• Model Choice: Certain cell lines may exhibit variable sensitivity to CB-5083 due to differential p97 expression or proteostasis capacity. Validate findings in multiple cancer models, including those highlighted in "CB-5083: Precision Targeting of p97 to Dissect ER Protein...", which details cell line-dependent responses.
• Control Experiments: Employ p97 knockdown (siRNA/shRNA) or alternative p97 inhibitors as orthogonal controls to confirm on-target effects and rule out compound-specific artifacts.

Future Outlook: CB-5083 as a Platform for Proteostasis and Lipid Homeostasis Research

The continued development of CB-5083 as a research tool and clinical candidate is poised to catalyze new discoveries at the intersection of protein degradation, ER stress, and lipid metabolism. By enabling precise, tunable disruption of p97-dependent pathways, CB-5083 empowers mechanistic studies spanning oncology, neurodegeneration, and metabolic disease. The reference work by Carrasquillo Rodríguez et al. (2024) sets the stage for future research integrating p97 inhibition with ER membrane dynamics and lipid droplet regulation, providing a template for systems-level investigations.

Moreover, as highlighted in "CB-5083: Unraveling p97 Inhibition for Advanced Cancer and...", CB-5083’s unique profile as a selective, orally bioavailable p97 inhibitor makes it an indispensable asset for both fundamental and translational researchers exploring the boundaries of protein and lipid homeostasis in cancer and beyond.

For detailed protocols, mechanistic insights, and compound ordering, visit the official CB-5083 product page.